Navigation Links
Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement

Agreement Underscores Morphotek's Commitment to the Development of Farletuzumab for Ovarian Cancer

Agreement Highlights Lonza's Ability to Offer Specialty Development and Manufacturing Solutions

EXTON, Pa. and BASEL, Switzerland, May 19 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, and Lonza Group Ltd jointly announced today that they have executed a manufacturing services agreement to support the development and manufacturing of a subset of antibodies in Morphotek's therapeutic antibody pipeline. The agreement will reserve capacity for commercial manufacturing of Morphotek's lead compound farletuzumab (also known as MORAb-003), which recently entered Phase III clinical trials for ovarian cancer under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). The collaboration between both parties already encompasses several other monoclonal antibodies currently in clinical or preclinical development.

"Lonza is an ideal partner and collaborator on this project," said Philip Sass, PhD, Executive Vice President and Chief Operating Officer of Morphotek. "They have a great deal of experience and expertise with large scale expression and purification of commercial antibody products. They have demonstrated their ability to develop high-quality material and documentation with several of our programs and serve as an extension of our development team at Morphotek. Based on our working experience, we are confident that Lonza will meet our production, quality goals and timelines for our antibody programs."

"Lonza is excited to participate in supporting the commercial manufacturing of Morphotek's lead compound, farletuzumab," said Stephan Kutzer, Head of Lonza Biopharmaceuticals. "Lonza looks forward to continuing and expanding the Morphotek relationship for both development and manufacturing services using Lonza's proprietary GS Gene Expression System(TM) toward their pipeline of promising compounds."

Through the use of its proprietary MORPHODOMA(R) technology, Morphotek develops optimized antibodies, including antibodies optimized for affinity and/or titer, for therapeutic applications and high-titer manufacturing cell lines. The antibodies within the company's pipeline are targeted against antigens licensed from its collaborative partners. Through its technology and collaborations, the company remains committed to bringing a new treatment option for patients with ovarian cancer.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients, both chemically and biologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at

About Morphotek

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, is a biopharmaceutical company specializing in the development of protein and antibody products through the use of novel and proprietary technologies. These technologies have been successfully applied to a variety of molecules that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery. For more information about Eisai, please visit

    For further Information:
    Lonza                            Lonza
    Head Corporate Communications    Media Relations
    Janet White                      Dominik Werner
    Tel +41 61 316 8566              Tel +41 61 316 8798
    Fax +41 61 316 9566              Fax +41 61 316 9798  

    Investor Relations
    Alexandre Pasini
    Tel +41 61 316 8835
    Fax +41 61 316 9835

    Morphotek(R), Inc.
    Executive Vice President and Chief Operating Officer
    Philip M. Sass
    Tel +1-610-423-6106

    Eisai Corporation of
    North America
    Senior Director, Corporate
    Judee Shuler

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
2. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
3. ImClone Systems and Lonza Walkersville to Discuss Paperless QC Micro at PDA Annual Meeting
4. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
5. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
6. Simcere Pharmaceutical Group Appoints Dr. Peng Wang as Chief Scientific Officer
7. Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results
8. Tiens Biotech Group (USA) Reports First Quarter Results
9. Adipose-derived Stem Cells Could Help Traumatic Brain Injury Patients, Says Bio-Matrix Scientific Groups, Entest BioMedical Inc. Researcher
10. CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems
11. Nanosys Licenses Nanowire Technology to QuantuMDx Group for Next Generation Diagnostic and Sequencing Technologies
Post Your Comments:
(Date:10/13/2015)... October 13, 2015      Q ... company, has entered into a strategic relationship with Wombat ... and Paris, France based strategic ... --> This collaborative arrangement gives Q BioMed ... advisory team as well as long established pharmaceutical industry ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Clinovo recently ... expertise to the company’s fast growing clinical data solutions business. , Jeff Parr has ... companies of all sizes, including Avery Dennison, Thermo Fisher, and Ab Sciex to name ...
(Date:10/12/2015)... BRUSSELS , Oct. 12, 2015  Amgen (NASDAQ: ... additional findings from an exploratory sub-study of the previously reported ... today in an oral plenary session at the American Society ... Seattle . 2 ... small exploratory sub-study data showed that, at month 12, the ...
(Date:10/12/2015)... October 12, 2015 cell surface marker ... by 2022, according to a new report by Grand View ... rise in incidence of oncology diseases and other cell-associated disorders. ... expected to reach USD 6.49 billion by 2022, according to ... in demand can be attributed to rise in incidence of ...
Breaking Biology Technology:
(Date:10/12/2015)... October 12, 2015 NXTD ) ("NXT-ID" ... growing mobile commerce market, reports on the recent SNS Future ... . --> NXTD ) ("NXT-ID" or the "Company"), ... market, reports on the recent SNS Future in Review Conference ... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ...
(Date:10/8/2015)... LAKE CITY , 8. Oktober 2015 ... TRCK), ein global tätiges Unternehmen des Bereiches ... einem Vertrag mit der Gefängnisbehörde Virginias (Department ... dessen Rahmen elektronische Überwachungsdienste für alle Strafen ... Derek Cassell , Präsident für den ...
(Date:10/6/2015)... 2015 Track Group, Inc. (OTCQX: TRCK), a ... signed a contract with the Virginia Department of Corrections ... of sentences under the Department,s oversight. Derek ... contract with the Virginia DOC will expand our footprint ... our position as a trusted leader in offender electronic ...
Breaking Biology News(10 mins):